Cargando…

Development of favipiravir loaded PLGA nanoparticles entrapped in in-situ gel for treatment of Covid-19 via nasal route

In 2019 the emergence of SARS-COV-2 caused pandemic situation worldwide and claimed ∼6.4 M lives (WHO 2022). Favipiravir (FAV) is recommended as a therapy for Covid-19 which belongs to BCS class III with a short half-life of 2–5.5h. Thus, the objective of current study was the development of favipir...

Descripción completa

Detalles Bibliográficos
Autores principales: Gattani, Vaishnavi, Dawre, Shilpa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745979/
https://www.ncbi.nlm.nih.gov/pubmed/36530548
http://dx.doi.org/10.1016/j.jddst.2022.104082